Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy.
Quinn CH, Beierle AM, Hutchins SC, Marayati R, Bownes LV, Stewart JE, Markert HR, Erwin MH, Aye JM, Yoon KJ, Friedman GK, Willey CD, Markert JM, Beierle EA.
Quinn CH, et al. Among authors: markert hr.
Cancers (Basel). 2022 Feb 1;14(3):762. doi: 10.3390/cancers14030762.
Cancers (Basel). 2022.
PMID: 35159029
Free PMC article.